List view / Grid view
The first long-acting injectable PrEP option proven superior to daily…
The first long-acting injectable PrEP option proven superior to daily oral FTC/TDF in reducing HIV acquisition, has been approved in the European Union (EU).
Sublicence agreements signed by the Medicines Patent Pool (MPP) and…
Sublicence agreements signed by the Medicines Patent Pool (MPP) and three generic manufacturers could enable millions to access a long-acting HIV medicine.
Under a new agreement, licenced manufacturers will be able to…
Under a new agreement, licenced manufacturers will be able to supply generic versions of ViiV’s long-acting cabotegravir HIV pre-exposure prophylaxis (PrEP) medication to developing nations.
Ambitions to reach greater numbers of patients with unmet need…
Ambitions to reach greater numbers of patients with unmet need have fuelled some benevolent plans from bio/pharmaceutical companies ViiV Healthcare and Sandoz.
Marketing authorisation in the EU has been given to Tivicay…
Marketing authorisation in the EU has been given to Tivicay (dolutegravir) dispersible tablets to treat HIV in certain paediatric patients.
The FDA has approved Tivicay (dolutegravir) and Tivicay PD (dolutegravir)…
The FDA has approved Tivicay (dolutegravir) and Tivicay PD (dolutegravir) dispersible tablets to treat HIV in children at least four weeks old and weighing at least 3kg.
The first regulatory approval for Cabenuva (cabotegravir and rilpivirine) has…
The first regulatory approval for Cabenuva (cabotegravir and rilpivirine) has been granted by Health Canada, in conjunction with use of Vocabria.
ViiV Healthcare has filed submissions to the FDA and EMA…
ViiV Healthcare has filed submissions to the FDA and EMA for the first dispersible formulation of dolutegravir (DTG) for children living with HIV.
